News | Cardiac Imaging | April 25, 2019

Women With Coronary Artery Wall Thickness at Risk for Heart Disease

Study underscores cardiac MRI as promising tool for early detection of coronary artery disease

Women With Coronary Artery Wall Thickness at Risk for Heart Disease

April 25, 2019  – The thickness of the coronary artery wall as measured by magnetic resonance imaging (MRI) is an independent marker for heart disease in women, according to a study published in the journal Radiology: Cardiothoracic Imaging.1

Previous research has found limitations in cardiovascular risk assessment for women. For instance, there is evidence that the commonly used Framingham Risk Score, which provides estimates of cardiovascular disease risk based on age, sex and other factors, underestimates the chance of heart attacks and other cardiovascular events in asymptomatic women. Imaging tools like coronary computed tomography angiography (CCTA) tend to be used in patients with symptoms or more advanced cardiovascular disease, but are not recommended for liberal use in risk assessment among the general population with no cardiac symptoms.

Recently, cardiac MRI has emerged as a promising tool for early detection of coronary artery disease. MRI can detect thickening in the walls of the arteries, a change that occurs earlier in the course of heart disease than stenosis, or narrowing of the arteries.

“Despite the significant advances in CCTA technology, it is not appropriate to send all asymptomatic people to CCTA because of the exposure to radiation and chemical dyes used for imaging,” said study lead author Khaled Z. Abd-Elmoniem, Ph.D., M.H.S., from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH) in Bethesda, Md. “MRI might be a safe alternative that can be used more broadly to assist in the diagnosis of coronary artery disease without exposing patients to a procedure that carries some risk. The advantage of MRI in this situation is that it can tell us that there is a thickening before stenosis, which is difficult to do with CCTA.”

Over a period of years, Abd-Elmoniem and colleagues developed and refined an MRI technique that adjusts for the motions of breathing and the beating heart to directly visualize coronary wall thickness. They used the technique to assess coronary artery disease in 62 women and 62 men with low to intermediate risks based on their Framingham scores. The patients also underwent CCTA to investigate the association between vessel wall thickness and CCTA-based coronary artery disease scores.

The results showed stark differences between the two groups.

“When we separated the patients into men and women, coronary artery disease in men was, as expected, associated with aging and a high Framingham score,” said Abd-Elmoniem. “However, in women, both age and the Framingham score were not factors. Vessel wall thickness, as measured by MRI, was the strongest variable associated with coronary artery disease.”

The results point to a potential future role for vessel wall thickness measurements in identifying opportunities for early lifestyle changes or treatment in a young, asymptomatic population. Unlike CCTA, cardiac MRI does not require radiation or contrast dyes.

“A single image and measurement of coronary vessel wall thickness with MRI can be used to gauge the extent of coronary plaque in asymptomatic women, who then can be appropriately referred for further exams and/or treatment,” said Abd-Elmoniem.

While further studies are needed, these results emphasize the unique nature of coronary artery disease development in women compared to men, and show that MRI could one day be a useful tool in the prevention and management of the disease in women, especially for those with intermediate risk.

“MRI provides another way to help guide physicians toward therapy,” said NIDDK’s Ahmed M. Gharib, M.D., a co-author on the paper. “Since it can be repeated, it can also be useful in monitoring the effectiveness of any therapy.”

Gharib, who heads the NIDDK Biomedical and Metabolic Imaging Branch, said the study results represent the fruits of a collaboration across multiple disciplines.

“This is a wonderful example of how a multidisciplinary team of biomedical engineers and radiologists can expedite translational research to clinical radiological applications,” he said.

For more information: www.pubs.rsna.org/journal/radiology

 

Reference

1. Ghanem A.M., Matta J.R., Elgarf R., et al. Sexual Dimorphism of Coronary Artery Disease in a Low- and Intermediate-Risk Asymptomatic Population: Association with Coronary Vessel Wall Thickness at MRI in Women. Radiology: Cardiothoracic Imaging, published online April 25, 2019. https://doi.org/10.1148/ryct.2019180007

Related Content

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Videos | Computed Tomography (CT) | July 19, 2019
Quynh Truong, M.D., MPH, associate professor of radio
Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
FDA Clears Koios DS Breast 2.0 AI-based Software
News | Ultrasound Women's Health | July 11, 2019
Koios Medical announced its second 510(k) clearance from the U.S. Food and Drug Administration (FDA).
Mednax National Cardiac Centers of Excellence Program Highlighted at SCCT 2019
News | CT Angiography (CTA) | July 11, 2019
Mednax Inc. and Mednax Radiology Solutions announced that Chief Medical Officer Ricardo C. Cury, M.D., FSCCT, will...